Current Report No: 19/2024
Date: 13.09.2024 r.
Legal Basis: Article 56_1__2_ of the Act on Public Offering – Current and
Periodic Information
The Management Board of Medicalgorithmics S.A. with its registered office in Warsaw _the “Issuer”, the “Company”_, hereby announces that on 13 September 2024 it received information on the adoption of Resolution No. 1134/2024 of the Management Board of the Warsaw Stock Exchange S.A. _”WSE”_ on the admission and introduction to exchange trading on the WSE Main Market of series J bearer ordinary shares of Medicalgorithmics S.A. _the “Resolution”_.
Pursuant to the Resolution, 1,194,331_one million one hundred and ninety-four thousand three hundred and thirty-one_ series J bearer common shares of the Company carrying ISIN code PLMDCLG00056_the “Shares”_, with a nominal value of 0.10 _ten groszy_each, were admitted to trading on the main market.
Pursuant to the Resolution, the Shares will be listed on the main market as of September 20, 2024, subject to the assimilation of the Shares by the National Securities Depository _Krajowy Depozyt Papierów Wartościowych S.A._ on September 20, 2024, with the Company’s shares traded on the stock exchange, under the code PLMDCLG00015. The Company will announce
the assimilation of the Shares in a separate current report.
The Company reminds that the Shares were issued in accordance with the Resolution No. 4 of the Company’s Extraordinary General Meeting of October 28, 2022 Increase of the Company’s share capital through issue of series I, J, K and L shares; waiver of existing shareholders’ subscription rights; private subscription offer for a designated entity; and change of Article 5 _1_ and _2_ of the Articles of Association. The shares were registered with the National Securities Depository on March 7, 2023, as the Company announced in current report number 8/2023 on March 8, 2023.
The Company reminds that in the current report No. 55/2022 it informed on October 1, 2022, that 4,976,384 Shares were acquired by Biofund Capital Management LLC with its registered office in Miami _USA_. These shares are to be introduced to trading under the applicable exceptions to the obligation to prepare an issue prospectus, and the planned date of introducing all these shares to trading has been set at the end of 2026.